MoonLake Immunotherapeutics (NASDAQ:MLTX) Expected to Post Q2 2024 Earnings of ($0.25) Per Share

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Research analysts at Lifesci Capital issued their Q2 2024 earnings per share (EPS) estimates for shares of MoonLake Immunotherapeutics in a research report issued on Tuesday, May 7th. Lifesci Capital analyst R. Katkhuda forecasts that the company will earn ($0.25) per share for the quarter. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.11) per share. Lifesci Capital also issued estimates for MoonLake Immunotherapeutics’ Q3 2024 earnings at ($0.29) EPS, Q4 2024 earnings at ($0.31) EPS and FY2024 earnings at ($1.07) EPS.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03).

Other research analysts have also issued reports about the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $66.00 target price on shares of MoonLake Immunotherapeutics in a research report on Wednesday. Wolfe Research initiated coverage on MoonLake Immunotherapeutics in a report on Thursday, February 15th. They issued an “outperform” rating and a $77.00 price objective on the stock. The Goldman Sachs Group assumed coverage on MoonLake Immunotherapeutics in a report on Tuesday, April 2nd. They set a “neutral” rating and a $62.00 target price for the company. Wedbush restated an “outperform” rating and issued a $92.00 price target on shares of MoonLake Immunotherapeutics in a report on Wednesday, March 13th. Finally, William Blair reiterated an “outperform” rating and set a $92.00 price objective on shares of MoonLake Immunotherapeutics in a research note on Monday, February 26th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $74.46.

MoonLake Immunotherapeutics Price Performance

Shares of MLTX stock opened at $42.63 on Thursday. MoonLake Immunotherapeutics has a 1-year low of $24.31 and a 1-year high of $64.98. The firm’s 50-day simple moving average is $46.03 and its 200-day simple moving average is $50.77. The firm has a market cap of $2.72 billion, a P/E ratio of -56.09 and a beta of 1.29.

Insider Buying and Selling

In other MoonLake Immunotherapeutics news, CEO Da Silva Jorge Santos sold 4,740 shares of MoonLake Immunotherapeutics stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $55.89, for a total transaction of $264,918.60. Following the sale, the chief executive officer now directly owns 2,982,814 shares in the company, valued at approximately $166,709,474.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Da Silva Jorge Santos sold 4,740 shares of the business’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $55.89, for a total value of $264,918.60. Following the completion of the sale, the chief executive officer now owns 2,982,814 shares of the company’s stock, valued at approximately $166,709,474.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Kristian Reich sold 10,000 shares of the stock in a transaction dated Wednesday, February 14th. The stock was sold at an average price of $62.43, for a total transaction of $624,300.00. Following the transaction, the insider now directly owns 130,071 shares in the company, valued at approximately $8,120,332.53. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 166,981 shares of company stock worth $9,490,674. 15.27% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in MLTX. FMR LLC raised its holdings in shares of MoonLake Immunotherapeutics by 0.6% during the third quarter. FMR LLC now owns 3,397,253 shares of the company’s stock worth $193,643,000 after purchasing an additional 19,508 shares during the period. Avoro Capital Advisors LLC grew its holdings in shares of MoonLake Immunotherapeutics by 29.0% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,580,000 shares of the company’s stock valued at $155,806,000 after purchasing an additional 580,001 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of MoonLake Immunotherapeutics by 9.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,314,012 shares of the company’s stock worth $139,744,000 after purchasing an additional 196,144 shares during the period. Adage Capital Partners GP L.L.C. lifted its holdings in shares of MoonLake Immunotherapeutics by 42.3% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 1,952,703 shares of the company’s stock worth $111,304,000 after purchasing an additional 580,375 shares during the last quarter. Finally, Finepoint Capital LP boosted its position in MoonLake Immunotherapeutics by 170.1% during the 4th quarter. Finepoint Capital LP now owns 895,000 shares of the company’s stock valued at $54,049,000 after purchasing an additional 563,584 shares during the period. Institutional investors and hedge funds own 93.85% of the company’s stock.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.